Hematologic Diseases

Expanding access to hematopoietic stem cell transplants for patients in need

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

  • PRESERVE I Study

    Phase 2
    0
    I
    II
    III
    IV

    A first-in-human, multi-center, single-arm study of HLA-partially-matched allogenic cryopreserved deceased donor bone marrow to treat patients with hematologic malignancies. The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.

    Related Products

    HPC, Marrow

    Partners

    NMDP / Be the Match / CIBMTR

  • Graft-versus-host Disease (GVHD)

    Pre-Clinical
    0
    I
    II
    III
    IV

    Evaluating the use of Ossium's mesenchymal stem cell product to treat steroid-refractory acute GVHD in adult and pediatric patients who previously had a hematopoietic cell transplantation (HCT) for acute leukemia and myelodysplastic syndromes

    Related Products

    MSCs

Organ Transplant Rejection

Allowing organ transplant recipients to lead healthy lives without immunosuppression

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

  • Multivisceral Transplantation

    Phase 1
    0
    I
    II
    III
    IV

    Phase 1 safety and feasibility clinical trial with the objective of inducing tolerance in intestinal transplant patients by establishing mixed Chimerism via infusion of Ossium’s selected CD34+ cells processed from the organ donor's bone marrow.

    Related Products

    Selected CD34+ Cells

    Partners

    Columbia University

Orthopedic Trauma

Leveraging Ossium's cell therapy expertise to develop a next-generation cellularized bone matrix allograft

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

  • Ossigraft™ Cellular Bone Matrix

    Commercial
    0
    I
    II
    III
    IV

    Ossigraft™ is a cellularized bone matrix allograft containing a formulation of viable cryopreserved cells in their native bone niche. Ossigraft™ is available in a variety of sizes and is intended for the repair, replacement, and reconstruction of musculoskeletal defects of the spine, pelvis, or extremities. The product is a minimally manipulated HCT/P regulated by the FDA under section 361 of the Public Health Service Act and 21 CFR Part 1271 and does not require premarket authorization. Ossium Health complies with Good Tissue Practices and is an FDA-registered Tissue Establishment.

    Related Products

    Ossigraft™ Cellularized Bone Matrix

Partner with Us

Let's work together to revolutionize treatment for patients suffering from hematologic diseases, organ transplant rejection, and orthopedic trauma.